Total Price: $0.00
Contact Information
Recombinant Human CD48 Protein (His Tag)
SKU: PKSH033401-50
Recombinant Human CD48 Protein (His Tag)
| SKU # | PKSH033401 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | B-lymphocyte activation marker BLAST-1, BCM1, BCM1 surface antigen, BLAST1, CD48, CD48 antigen, Leukocyte antigen MEM-102, SLAMF2, TCT.1, hCD48, mCD48 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Gln27-Ser220 |
| Accession | P09326 |
| Calculated Molecular Weight | 50.3 kDa |
| Observed Molecular Weight | 71 kDa |
| Tag | C-Fc-His |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
CD48 antigen; also known as B-lymphocyte activation marker BLAST-1; BCM1 surface antigen; Leukocyte antigen MEM-102; TCT.1; CD48; BCM1;and BLAST1; CD48 contains one Ig-like C2-type domain and one Ig-like V-type domain; but does not have a transmembrane domain; however; but is held at the cell surface by a GPI anchor via a C-terminal domain which maybe cleaved to yield a soluble form of the receptor. CD48 may facilitate interaction between activated lymphocytes and be involved in regulating T-cell activation. CD48 plays a vital role as an environmental sensor for regulating progenitor cell numbers and inhibiting tumor development. It is suggested that the anti-CD48 mAb has the potential to become an effective therapeutic mAb against multiple myeloma.